Skip to content

West Virginia Medicaid

Does West Virginia Medicaid cover Zepbound?

No. West Virginia Medicaid's policies on file exclude Zepbound for weight loss on Medicaid plans.

Policy document

  • West Virginia Medicaid Medicaid prior authorization policy

    West Virginia Medicaid · PA policy · Medicaid

    Effective July 1, 2025. Verified June 3, 2026.

    View PDF Download Original insurer source
  • Medicaid: Not covered. Agents used for the purpose of weight loss are typically a benefit exclusion and not covered by West Virgin...

Earliest policy review June 3, 2026. How we verify · Check your exact plan

Full requirements: Zepbound for Weight Loss (1 plan type)

Applies to Medicaid plans.

Not covered

Agents used for the purpose of weight loss are typically a benefit exclusion and not covered by West Virginia Medicaid. Coverage of Zepbound will only be considered for a diagnosis of OSA in adults with obesity.

Policy note: West Virginia Medicaid explicitly excludes weight loss as a covered indication for Zepbound. Coverage is only considered for OSA in adults with obesity.

Policy effective July 1, 2025 · verified June 3, 2026 · source: West Virginia Medicaid Medicaid prior authorization policy · View policy document (PDF)

Open on its own page →

Full requirements: Zepbound for Obstructive Sleep Apnea (OSA) (1 plan type)

Applies to Medicaid plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Initial Approval — OSA in Adults with Obesity (No Concurrent T2DM)

All of:

  • Patient is within the FDA-labeled age range (adults)
  • Diagnosis of moderate to severe OSA confirmed by sleep study within the past 12 months with AHI ≥ 15 events/hour
  • Diagnosis of obesity with documented BMI ≥ 30 kg/m² within the past 3 months (date and BMI result stated on request)
  • Patient has been prescribed or counseled on use of CPAP as a potential therapy
  • Patient has received counseling on chronic weight management (increased physical activity and reduced calorie diet) and will continue ongoing counseling during treatment
  • Patient is not receiving Zepbound in combination with other tirzepatide-containing products or any other GIP/GLP-1 class agents

Initial Approval — OSA in Adults with Obesity and Concurrent Type II Diabetes

All of:

  • Patient is within the FDA-labeled age range (adults)
  • Diagnosis of moderate to severe OSA confirmed by sleep study within the past 12 months with AHI ≥ 15 events/hour
  • Diagnosis of obesity with documented BMI ≥ 30 kg/m² within the past 3 months (date and BMI result stated on request)
  • Patient has been prescribed or counseled on use of CPAP as a potential therapy
  • Patient has received counseling on chronic weight management (increased physical activity and reduced calorie diet) and will continue ongoing counseling during treatment
  • Patient has concurrent diagnosis of Type II Diabetes Mellitus and has been trialed on a preferred GLP-1 (indicated for Type II DM) compliantly for three months with treatment failure
  • Patient is not receiving Zepbound in combination with other tirzepatide-containing products or any other GIP/GLP-1 class agents

Documentation to bring

  • Sleep study results within the past 12 months confirming AHI ≥ 15 events/hour
  • Documented BMI ≥ 30 kg/m² with date and results of most recent weight and BMI calculation within the past 3 months
  • Documentation of prescription or counseling on CPAP as a potential therapy
  • Documentation of counseling on chronic weight management (increased physical activity and reduced calorie diet)
  • If concurrent Type II Diabetes diagnosis: documentation of compliant 3-month trial of a preferred GLP-1 (indicated for Type II DM) and treatment failure
  • Attestation that patient is not receiving Zepbound in combination with other tirzepatide-containing products or other GIP/GLP-1 class agents

Quantity limits

  • all strengths — 30-day supply

Approval and renewal

  • Renewal: every 6 months
  • Renewal: At least 5% weight loss from the starting weight.
  • Renewal: Clinical improvement of OSA while on Zepbound (e.g., patient-reported improvement in daytime sleepiness, partner-reported reduction of snoring/pauses in breathing, reduction of AHI events). Patient must also tolerate at least 10 mg maintenance dose, demonstrate documented compliance, and continue reduced calorie diet and increased physical activity. Initial BMI, OSA diagnosis, and GLP-1 step-therapy requirements are not explicitly re-verified at continuation.
  • Renewal: Staying on a maintenance dose of at least 10 mg.

Not covered when

  • Concurrent use with other tirzepatide-containing products
  • Concurrent use with other GIP/GLP-1 class agents
  • Patients with concurrent Type II Diabetes who have not failed a 3-month compliant trial of a preferred GLP-1 indicated for Type II DM

Policy note: Initial approvals may be authorized for 150 days. Further approvals may be granted for 6 months after all continuation criteria are met. All fills are limited to a 30-day supply. OSA confirmation requires AHI ≥ 15 events/hour (moderate to severe). CPAP must be prescribed or counseled — a full prior trial/failure is not required. Patients with concurrent T2DM must have tried a preferred GLP-1 (for T2DM) for 3 months with failure before Zepbound is approved. Reauthorization requires: documented compliance, tolerance of at least 10 mg maintenance dose, continued diet/activity plan adherence, clinical improvement of OSA, AND documented weight loss >5% or maintenance of initial 5% weight loss.

Policy effective July 1, 2025 · verified June 3, 2026 · source: West Virginia Medicaid Medicaid prior authorization policy · View policy document (PDF)

Open on its own page →

If weight loss isn't covered on your plan

West Virginia Medicaid has separate Zepbound policies that don't depend on that benefit:

Questions people ask
Does West Virginia Medicaid cover Zepbound?
No. West Virginia Medicaid's policies on file exclude Zepbound for weight loss on Medicaid plans.
How long does a Zepbound approval last with West Virginia Medicaid?
Obstructive Sleep Apnea (OSA) — Applies to Medicaid plans. Renewal: every 6 months.
What does West Virginia Medicaid require to renew Zepbound?
Obstructive Sleep Apnea (OSA) — Applies to Medicaid plans. At least 5% weight loss from the starting weight. Clinical improvement of OSA while on Zepbound (e.g., patient-reported improvement in daytime sleepiness, partner-reported reduction of snoring/pauses in breathing, reduction of AHI events). Patient must also tolerate at least 10 mg maintenance dose, demonstrate documented compliance, and continue reduced calorie diet and increased physical activity. Initial BMI, OSA diagnosis, and GLP-1 step-therapy requirements are not explicitly re-verified at continuation. Staying on a maintenance dose of at least 10 mg.
How current is this information?
The oldest review date among the policies on this page is June 3, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under West Virginia Medicaid: Mounjaro, Ozempic, Wegovy

Zepbound under other plans: Highmark, Alabama Medicaid, California Medicaid, Colorado Medicaid, Connecticut Medicaid, Delaware Medicaid, Illinois Medicaid, Indiana Medicaid

All insurance plans · All medications

Summary of West Virginia Medicaid's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.